Insulin icodec

Insulin icodec is an investigational ultralong-acting basal insulin analogue that is developed by Novo Nordisk.

Insulin icodec
Clinical data
ATC code
  • None
Identifiers
  • (1a-21a),(1b-29b)-Insulin (human), 14a-L-glutamic acid-16b-L-histidine-25b-L-histidine-29b-(N6-(N-(19-carboxy-1-oxononadecyl)-L-gamma-glutamyl-2-(2-(2-aminoethoxy)ethoxy)acetyl-2-(2-(2-aminoethoxy)ethoxy)acetyl)-L-lysine)-
CAS Number
DrugBank
UNII
KEGG
Chemical and physical data
FormulaC280H435N71O87S6
Molar mass6380.33 g·mol−1

It has a plasma half-life more than eight days[1] (compared to 25 hours of the previous longest-acting insulin analogue insulin degludec), making it a once-weekly basal insulin.[2] The substance is composed of two peptide chains, linked by a disulfide bridge. The 21 amino acid residue chain has two internal disulfide bridges and the second chain is 29 residues long.

Insulin icodec is the international nonproprietary name.[3]

Research

Based on a clinical trial, glycemic control was found to be non-inferior with once-weekly insulin icodec compared with once-daily insulin glargine U100.[4]

References
  1. Kjeldsen TB, Hubálek F, Hjørringgaard CU, Tagmose TM, Nishimura E, Stidsen CE, et al. (8 July 2021). "Molecular Engineering of Insulin Icodec, the First Acylated Insulin Analog for Once-Weekly Administration in Humans". Journal of Medicinal Chemistry. 64 (13): 8942–8950. doi:10.1021/acs.jmedchem.1c00257. ISSN 1520-4804. PMID 33944562. S2CID 233718893.
  2. Kjeldsen TB, Hubálek F, Hjørringgaard CU, Tagmose TM, Nishimura E, Stidsen CE, et al. (July 2021). "Molecular Engineering of Insulin Icodec, the First Acylated Insulin Analog for Once-Weekly Administration in Humans". Journal of Medicinal Chemistry. 64 (13): 8942–8950. doi:10.1021/acs.jmedchem.1c00257. PMID 33944562. S2CID 233718893.{{cite journal}}: CS1 maint: overridden setting (link)
  3. World Health Organization (2021). "International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 85". WHO Drug Information. 35 (1). hdl:10665/340684.
  4. Rosenstock J, Bain SC, Gowda A, Jódar E, Liang B, Lingvay I, et al. (27 July 2023). "Weekly Icodec versus Daily Glargine U100 in Type 2 Diabetes without Previous Insulin". New England Journal of Medicine. 389 (4): 297–308. doi:10.1056/NEJMoa2303208. ISSN 1533-4406. PMID 37356066. S2CID 259249866.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.